MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential

Journal of Zhejiang University: Science B

Volumn 16, Issue 1, 2015, Pages 18-31

  Wang, Wei ^a   Luo, Yun ping ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Breast cancer; Diagnosis marker; MicroRNA; MicroRNA based therapy; Oncogene; Tumor suppressors

Indexed keywords

MICRORNA; MICRORNA 10B; MICRORNA 145; MICRORNA 155; MICRORNA 182; MICRORNA 19A; MICRORNA 200; MICRORNA 205; MICRORNA 21; MICRORNA 27A; MICRORNA 335; MICRORNA 9; UNCLASSIFIED DRUG; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; HUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR SUPPRESSOR GENE; ANIMAL; BLOOD; BREAST TUMOR; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MOUSE; RNA PROCESSING;

ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICRORNAS; NEOPLASM METASTASIS; ONCOGENES; RNA PROCESSING, POST-TRANSCRIPTIONAL;

EID: 84920863281     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1400184     Document Type: Review

References (147)

1. Ahmad, A., Aboukameel, A., Kong, D.J., et al., 2011. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res., 71(9):3400–3409. [doi:10.1158/0008-5472.CAN-10-0965]
2. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., et al., 2003. Prospective identification of tumorigenic breast cancer cells. PNAS, 100(7):3983–3988. [doi:10.1073/pnas.0530291100]
3. Andorfer, C.A., Necela, B.M., Thompson, E.A., et al., 2011. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol. Med., 17(6):313–319. [doi:10.1016/j.molmed.2011.01.006]
4. Asaga, S., Kuo, C., Nguyen, T., et al., 2011. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem., 57(1):84–91. [doi:10.1373/clinchem.2010.151845]
5. Barh, D., Malhotra, R., Ravi, B., et al., 2010. MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr. Oncol., 17(1):70–80. [doi:10.3747/co.v17i1.356]
6. Bartel, D.P., 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116(2):281–297. [doi:10.1016/S0092-8674(04)00045-5]
7. Bertucci, F., Finetti, P., Rougemont, J., et al., 2005. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res., 65(6): 2170–2178. [doi:10.1158/0008-5472.CAN-04-4115]
8. Bhaumik, D., Scott, G.K., Schokrpur, S., et al., 2008. Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells. Oncogene, 27(42):5643–5647. [doi:10.1038/onc.2008.171]
9. Blenkiron, C., Goldstein, L.D., Thorne, N.P., et al., 2007. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol., 8(10):R214. [doi:10.1186/gb-2007-8-10-r214]
10. Bockhorn, J., Yee, K., Chang, Y.F., et al., 2013. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res. Treat., 137(2):373–382. [doi:10.1007/s10549-012-2346-4]
11. Brabletz, T., Jung, A., Spaderna, S., et al., 2005. Migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat. Rev. Cancer, 5(9):744–749. [doi:10.1038/nrc1694]
12. Brognara, E., Fabbri, E., Aimi, F., et al., 2012. Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells. Int. J. Mol. Med., 30:S59. [doi:10.3892/ijo.2012.1632]
13. Buffa, F.M., Camps, C., Winchester, L., et al., 2011. MicroRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res., 71(17): 5635–5645. [doi:10.1158/0008-5472.CAN-11-0489]
14. Cai, J.C., Guan, H.Y., Fang, L.S., et al., 2013. MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. J. Clin. Invest., 123(2):566–579. [doi:10.1172/Jci65871]
15. Calin, G.A., Croce, C.M., 2006. MicroRNA signatures in human cancers. Nat. Rev. Cancer, 6(11):857–866. [doi:10.1038/nrc1997]
16. Cascio, S., D’Andrea, A., Ferla, R., et al., 2010. miR-20b modulates VEGF expression by targeting HIF-1α and STAT3 in MCF-7 breast cancer cells. J. Cell Physiol., 224(1):242–249. [doi:10.1002/Jcp.22126]
17. Cha, S.T., Chen, P.S., Johansson, G., et al., 2010. MicroRNA-519c suppresses hypoxia-inducible factor-1α expression and tumor angiogenesis. Cancer Res., 70(7):2675–2685. [doi:10.1158/0008-5472.CAN-09-2448]
18. Chan, J.A., Krichevsky, A.M., Kosik, K.S., 2005. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res., 65(14):6029–6033. [doi:10.1158/0008-5472.CAN-05-0137]
19. Chao, C.H., Chang, C.C., Wu, M.J., et al., 2014. MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. J. Clin. Invest., 124(7):3093–3106. [doi:10.1172/JCI73351]
20. Chen, W.X., Hu, Q., Qiu, M.T., et al., 2013. miR-221/222: promising biomarkers for breast cancer. Tumor Biol., 34(3):1361–1370. [doi:10.1007/s13277-013-0750-y]
21. Chen, X., Gao, C., Li, H.J., et al., 2010. Identification and characterization of microRNAs in raw milk during different periods of lactation, commercial fluid, and powdered milk products. Cell Res., 20(10):1128–1137. [doi:10.1038/cr.2010.80]
22. Cheng, C.W., Wang, H.W., Chang, C.W., et al., 2012. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast Cancer Res. Treat., 134(3):1081–1093. [doi:10.1007/s10549-012-2034-4]
23. Chiang, C.H., Hou, M.F., Hung, W.C., 2013. Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK. BBA-Gen. Subjects, 1830(4):3067–3076. [doi:10.1016/j.bbagen.2013.01.009]
24. Cittelly, D.M., Das, P.M., Spoelstra, N.S., et al., 2010. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol. Cancer, 9(1):317. [doi:10.1186/1476-4598-9-317]
25. Cookson, V.J., Bentley, M.A., Hogan, B.V., et al., 2012. Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell. Oncol., 35(4):301–308. [doi:10.1007/s13402-012-0089-1]
26. Croce, C.M., Calin, G.A., 2005. miRNAs, cancer, and stem cell division. Cell, 122(1):6–7. [doi:10.1016/j.cell.2005.06.036]
27. Cui, W.J., Zhang, S., Shan, C.L., et al., 2013. MicroRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway. FEBS J., 280(16):3962–3974. [doi:10.1111/febs.12398]
28. Cuk, K., Zucknick, M., Heil, J., et al., 2013. Circulating microRNAs in plasma as early detection markers for breast cancer. Int. J. Cancer, 132(7):1602–1612. [doi:10.1002/ijc.27799]
29. de Souza Rocha Simonini, P., Breiling, A., Gupta, N., et al., 2010. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor α in breast cancer cells. Cancer Res., 70(22): 9175–9184. [doi:10.1158/0008-5472.CAN-10-1318]
30. Ding, X.M., Park, S.I., McCauley, L.K., et al., 2013. Signaling between transforming growth factor β (TGF-β) and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial-mesenchymal transition and tumor metastasis. J. Biol. Chem., 288(15): 10241–10253. [doi:10.1074/jbc.M112.443655]
31. Dykxhoorn, D.M., Palliser, D., Lieberman, J., 2006. The silent treatment: siRNAs as small molecule drugs. Gene Therapy, 13(6):541–552. [doi:10.1038/sj.gt.3302703]
32. Dykxhoorn, D.M., Wu, Y.C., Xie, H.M., et al., 2009. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS ONE, 4(9):e7181. [doi:10.1371/journal.pone.0007181]
33. Eades, G., Yao, Y., Yang, M.H., et al., 2011. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J. Biol. Chem., 286(29):25992–26002. [doi:10.1074/jbc.M111.229401]
34. Ebert, M.S., Neilson, J.R., Sharp, P.A., 2007. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods, 4(9):721–726. [doi:10.1038/nmeth1079]
35. Esquela-Kerscher, A., Trang, P., Wiggins, J.F., et al., 2008. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle, 7(6):759–764. [doi:10.4161/cc.7.6.5834]
36. Farazi, T.A., Horlings, H.M., ten Hoeve, J.J., et al., 2011. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res., 71(13):4443–4453. [doi:10.1158/0008-5472.CAN-11-0608]
37. Frankel, L.B., Christoffersen, N.R., Jacobsen, A., et al., 2008. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem., 283(2):1026–1033. [doi:10.1074/jbc.M707224200]
38. Gao, J., Li, L.S., Wu, M.Q., et al., 2013. miR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS ONE, 8(6):e65138. [doi:10.1371/journal.pone.0065138]
39. Gilad, S., Meiri, E., Yogev, Y., et al., 2008. Serum microRNAs are promising novel biomarkers. PLoS ONE, 3(9):e3148. [doi:10.1371/journal.pone.0003148]
40. Goldberger, N., Walker, R.C., Kim, C.H., et al., 2013. Inherited variation in miR-290 expression suppresses breast cancer progression by targeting the metastasis susceptibility gene Arid4b. Cancer Res., 73(8):2671–2681. [doi:10.1158/0008-5472.CAN-12-3513]
41. Gregory, P.A., Bracken, C.P., Bert, A.G., et al., 2008. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle, 7(20):3112–3118. [doi:10.4161/cc.7.20.6851]
42. Gumireddy, K., Young, D.D., Xiong, X., et al., 2008. Small-molecule inhibitors of microRNA miR-21 function. Angew. Chem. Int. Ed., 47(39):7482–7484. [doi:10.1002/anie.200801555]
43. Guttilla, I.K., White, B.A., 2009. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J. Biol. Chem., 284(35):23204–23216. [doi:10.1074/jbc.M109.031427]
44. Hanke, M., Hoefig, K., Merz, H., et al., 2010. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol.-Semin. Orig. Invest., 28(6): 655–661. [doi:10.1016/j.urolonc.2009.01.027]
45. Haque, I., Banerjee, S., Mehta, S., et al., 2011. Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced signaling protein-2 (WISP-2) regulates microRNA-10b via hypoxia-inducible factor-1α-TWIST signaling networks in human breast cancer cells. J. Biol. Chem., 286(50):43475–43485. [doi:10.1074/jbc.M111.284158]
46. He, T., Qi, F.F., Jia, L., et al., 2014. MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2. J. Pathol., 232(5):499–508. [doi:10.1002/path.4324]
47. Heneghan, H.M., Miller, N., Kerin, M.J., 2010. Circulating miRNA signatures: promising prognostic tools for cancer. J. Clin. Oncol., 28(29):e573–e574. [doi:10.1200/JCO.2010.29.8901]
48. Hermeking, H., 2012. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat. Rev. Cancer, 12(9):613–626. [doi:10.1038/nrc3318]
49. Heyn, H., Engelmann, M., Schreek, S., et al., 2011. MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int. J. Cancer, 129(12):2797–2806. [doi:10.1002/ijc.25962]
50. Hu, J.J., Guo, H., Li, H.Y., et al., 2012. miR-145 regulates epithelial to mesenchymal transition of breast cancer cells by targeting OCT4. PLoS ONE, 7(9):e45965. [doi:10.1371/journal.pone.0045965]
51. Hu, X.W., Guo, J.Y., Zheng, L., et al., 2013. The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol. Cancer Res., 11(3):240–250. [doi:10.1158/1541-7786.MCR-12-0432]
52. Huang, Q.H., Gumireddy, K., Schrier, M., et al., 2008. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol., 10(2):202–210. [doi:10.1038/ncb1681]
53. Hwang, M.S., Yu, N., Stinson, S.Y., et al., 2013. miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. PLoS ONE, 8(6):e66502. [doi:10.1371/journal.pone.0066502]
54. Iorio, M.V., Croce, C.M., 2009. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol., 27(34): 5848–5856. [doi:10.1200/JCO.2009.24.0317]
55. Iorio, M.V., Ferracin, M., Liu, C.G., et al., 2005. MicroRNA gene expression deregulation in human breast cancer. Cancer Res., 65(16):7065–7070. [doi:10.1158/0008-5472.CAN-05-1783]
56. Iorio, M.V., Visone, R., Di Leva, G., et al., 2007. MicroRNA signatures in human ovarian cancer. Cancer Res., 67(18): 8699–8707. [doi:10.1158/0008-5472.CAN-07-1936]
57. Iorio, M.V., Casalini, P., Piovan, C., et al., 2009. MicroRNA-205 regulates HER3 in human breast cancer. Cancer Res., 69(6):2195–2200. [doi:10.1158/0008-5472.CAN-08-2920]
58. Jansson, M.D., Lund, A.H., 2012. MicroRNA and cancer. Mol. Oncol., 6(6):590–610. [doi:10.1016/j.molonc.2012.09.006]
59. Jiang, S.A., Zhang, H.W., Lu, M.H., et al., 2010. MicroRNA-155 functions as an oncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res., 70(8):3119–3127. [doi:10.1158/0008-5472.CAN-09-4250]
60. Johnson, S.M., Lin, S.Y., Slack, F.J., 2003. The time of appearance of the C. elegans let-7 microRNA is transcriptionally controlled utilizing a temporal regulatory element in its promoter. Dev. Biol., 259(2):364–379. [doi:10.1016/S0012-1606(03)00202-1]
61. Karnoub, A.E., Dash, A.B., Vo, A.P., et al., 2007. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449(7162):557–563. [doi:10.1038/nature06188]
62. Kim, V.N., 2005. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol., 6(5):376–385. [doi:10.1038/nrm1644]
63. Kong, W., He, L.L., Coppola, M., et al., 2010. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J. Biol. Chem., 285(23):17869–17879. [doi:10.1074/jbc.M110.101055]
64. Korner, C., Keklikoglou, I., Bender, C., et al., 2013. MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C ɛ (PKCɛ). J. Biol. Chem., 288(12):8750–8761. [doi:10.1074/jbc.M112.414128]
65. Korpal, M., Ell, B.J., Buffa, F.M., et al., 2011. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nature Med., 17(9): 1101–1108. [doi:10.1038/nm.2401]
66. Kota, J., Chivukula, R.R., O’Donnell, K.A., et al., 2009. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 137(6): 1005–1017. [doi:10.1016/j.cell.2009.04.021]
67. Kreso, A., Dick, J.E., 2014. Evolution of the cancer stem cell model. Cell Stem Cell, 14(3):275–291. [doi:10.1016/j.stem.2014.02.006]
68. Krützfeldt, J., Rajewsky, N., Braich, R., et al., 2005. Silencing of microRNAs in vivo with ‘antagomirs’. Nature, 438(7068): 685–689. [doi:10.1038/nature04303]
69. Lagos-Quintana, M., Rauhut, R., Yalcin, A., et al., 2002. Identification of tissue-specific microRNAs from mouse. Curr. Biol., 12(9):735–739. [doi:10.1016/S0960-9822(02)00809-6]
70. Lee, R.C., Feinbaum, R.L., Ambros, V., 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75(5):843–854. [doi:10.1016/0092-8674(93)90529-Y]
71. Lei, R., Tang, J., Zhuang, X., et al., 2014. Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis. Oncogene, 33(10):1287–1296. [doi:10.1038/onc.2013.65]
72. Li, J., Zhang, Y., Zhang, W., et al., 2013. Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation. Int. J. Surg. Oncol., 2013:875078. [doi:10.1155/2013/875078]
73. Li, L.Z., Zhang, C.Z., Liu, L.L., et al., 2014. miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis, 35(2):469–478. [doi:10.1093/carcin/bgt330]
74. Li, Q.Y., Zhu, F.F., Chen, P.X., 2012. miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer. Biochem. Biophys. Res. Commun., 424(1):28–33. [doi:10.1016/j.bbrc.2012.06.028]
75. Li, X., Roslan, S., Johnstone, C.N., et al., 2013. miR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. Oncogene, 33(31): 4077–4088. [doi:10.1038/onc.2013.370]
76. Liao, D., Liu, Z., Wrasidlo, W., et al., 2011. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomed.-Nanotechnol., 7(6):665–673. [doi:10.1016/j.nano.2011.03.001]
77. Lim, Y.Y., Wright, J.A., Attema, J.L., et al., 2013. Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. J. Cell Sci., 126(10):2256–2266. [doi:10.1242/jcs.122275]
78. Liu, X.X., Li, X.J., Zhang, B., et al., 2011. MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett., 585(9): 1363–1367. [doi:10.1016/j.febslet.2011.04.018]
79. Liu, Y., Zhao, J., Zhang, P.Y., et al., 2012. MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis. Med. Sci. Monitor, 18(8):Br299–Br308. [doi:10.12659/MSM.883262]
80. Luo, Q.F., Li, X.Y., Gao, Y., et al., 2013. miRNA-497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer. Cancer Cell Int., 13(1):95. [doi:10.1186/1475-2867-13-95]
81. Ma, L., Teruya-Feldstein, J., Weinberg, R.A., 2007. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449(7163):682–688. [doi:10.1038/nature06174]
82. Ma, L., Young, J., Prabhala, H., et al., 2010a. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol., 12(3):247–256. [doi:10.1038/Ncb2024]
83. Ma, L., Reinhardt, F., Pan, E., et al., 2010b. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol., 28(4):341–347. [doi:10.1038/nbt.1618]
84. Mani, S.A., Guo, W., Liao, M.J., et al., 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133(4):704–715. [doi:10.1016/j.cell.2008.03.027]
85. Meister, G., Landthaler, M., Dorsett, Y., et al., 2004. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA, 10(3):544–550. [doi:10.1261/rna.5235104]
86. Melo, S.A., Esteller, M., 2011. Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett., 585(13): 2087–2099. [doi:10.1016/j.febslet.2010.08.009]
87. Meng, F.Y., Henson, R., Lang, M., et al., 2006. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology, 130(7):2113–2129. [doi:10.1053/j.gastro.2006.02.057]
88. Meng, F.Y., Henson, R., Wehbe-Janek, H., et al., 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133(2):647–658. [doi:10.1053/j.gastro.2007.05.022]
89. Mertens-Talcott, S.U., Chintharlapalli, S., Li, M.R., et al., 2007. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res., 67(22):11001–11011. [doi:10.1158/0008-5472.CAN-07-2416]
90. Mitchell, P.S., Parkin, R.K., Kroh, E.M., et al., 2008. Circulating microRNAs as stable blood-based markers for cancer detection. PNAS, 105(30):10513–10518. [doi:10.1073/pnas.0804549105]
91. Mitra, A., Rostas, J.W., Dyess, D.L., et al., 2012. Micro-RNA-632 downregulates DNAJB6 in breast cancer. Lab. Invest., 92(9):1310–1317. [doi:10.1038/labinvest.2012.87]
92. Moriarty, C.H., Pursell, B., Mercurio, A.M., 2010. miR-10b targets Tiam1 implications for Rac activation and carcinoma migration. J. Biol. Chem., 285(27):20541–20546. [doi:10.1074/jbc.M110.121012]
93. Mukhtar, R.A., Nseyo, O., Campbell, M.J., et al., 2011. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert. Rev. Mol. Diagn., 11(1):91–100. [doi:10.1586/erm.10.97]
94. Nassirpour, R., Mehta, P.P., Baxi, S.M., et al., 2013. miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS ONE, 8(4):e62170. [doi:10.1371/journal.pone.0062170]
95. Ng, E.K.O., Li, R.F.N., Shin, V.Y., et al., 2013. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS ONE, 8(1):e53141. [doi:10.1371/journal.pone.0053141]
96. Nguyen, D.P., Li, J., Yadav, S.S., et al., 2014. Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer. BJU Int., 114(2):168–176. [doi:10.1111/bju.12488]
97. Nimmo, R.A., Slack, F.J., 2009. An elegant mirror: microRNAs in stem cells, developmental timing and cancer. Chromosoma, 118(4):405–418. [doi:10.1007/s00412-009-0210-z]
98. O’Hara, S.P., Mott, J.L., Splinter, P.L., et al., 2009. MicroRNAs: key modulators of posttranscriptional gene expression. Gastroenterology, 136(1):17–25. [doi:10.1053/j.gastro.2008.11.028]
99. Okuda, H., Xing, F., Pandey, P.R., et al., 2013. miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res., 73(4):1434–1444. [doi:10.1158/0008-5472.CAN-12-2037]
100. Ørom, U.A., Kauppinen, S., Lund, A.H., 2006. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene, 372:137–141. [doi:10.1016/j.gene.2005.12.031]
101. Ovcharenko, D., Kelnar, K., Johnson, C., et al., 2007. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res., 67(22):10782–10788. [doi:10.1158/0008-5472.CAN-07-1484]
102. Park, N.J., Zhou, H., Elashoff, D., et al., 2009. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res., 15(17): 5473–5477. [doi:10.1158/1078-0432.CCR-09-0736]
103. Png, K.J., Yoshida, M., Zhang, X.H.F., et al., 2011. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev., 25(3):226–231. [doi:10.1101/gad.1974211]
104. Png, K.J., Halberg, N., Yoshida, M., et al., 2012. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature, 481(7380):190–194. [doi:10.1038/nature10661]
105. Qi, J., Wang, J., Katayama, H., et al., 2013. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma, 60(2):135–142. [doi:10.4149/neo_2013_018]
106. Radojicic, J., Zaravinos, A., Vrekoussis, T., et al., 2011. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle, 10(3):507–517. [doi:10.4161/cc.10.3.14754]
107. Rivas, M.A., Venturutti, L., Huang, Y.W., et al., 2012. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res., 14(3): R77. [doi:10.1186/bcr3187]
108. Rubin, R., Arzumanyan, A., Soliera, A.R., et al., 2007. Insulin receptor substrate (IRS)-1 regulates murine embryonic stem (mES) cells self-renewal. J. Cell. Physiol., 213(2): 445–453. [doi:10.1002/jcp.21185]
109. Sachdeva, M., Mo, Y.Y., 2010. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res., 70(1):378–387. [doi:10.1158/0008-5472.CAN-09-2021]
110. Schee, K., Boye, K., Abrahamsen, T.W., et al., 2012. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer, 12(1):505. [doi:10.1186/1471-2407-12-505]
111. Scheel, C., Eaton, E.N., Li, S.H.J., et al., 2011. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell, 145(6):926–940. [doi:10.1016/j.cell.2011.04.029]
112. Shipitsin, M., Polyak, K., 2008. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab. Invest., 88(5):459–463. [doi:10.1038/labinvest.2008.14]
113. Si, M.L., Zhu, S., Wu, H., et al., 2007. miR-21-mediated tumor growth. Oncogene, 26(19):2799–2803. [doi:10.1038/sj.onc.1210083]
114. Sica, A., Larghi, P., Mancino, A., et al., 2008. Macrophage polarization in tumour progression. Semin. Cancer Biol., 18(5):349–355. [doi:10.1016/j.semcancer.2008.03.004]
115. Smith, A.L., Iwanaga, R., Drasin, D.J., et al., 2012. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene, 31(50):5162–5171. [doi:10.1038/onc.2012.11]
116. Song, S.J., Poliseno, L., Song, M.S., et al., 2013. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell, 154(2):311–324. [doi:10.1016/j.cell.2013.06.026]
117. Sorlie, T., Perou, C.M., Tibshirani, R., et al., 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS, 98(19):10869–10874. [doi:10.1073/pnas.191367098]
118. Sossey-Alaoui, K., Downs-Kelly, E., Das, M., et al., 2011. WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade. Int. J. Cancer, 129(6): 1331–1343. [doi:10.1002/ijc.25793]
119. Spizzo, R., Nicoloso, M.S., Lupini, L., et al., 2010. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-α in human breast cancer cells. Cell Death Differ., 17(2):246–254. [doi:10.1038/cdd.2009.117]
120. Stinson, S., Lackner, M.R., Adai, A.T., et al., 2011. miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci. Signal., 4(186):pt5. [doi:10.1126/scisignal.2002258]
121. Sun, X., Fan, C., Hu, L.J., et al., 2012. Role of let-7 in maintaining characteristics of breast cancer stem cells. Chin. J. Cell. Mol. Immunol., 28(8):789–792 (in Chinese).
122. Tang, W., Yu, F., Yao, H., et al., 2014. miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene, 33(20):2629–2638. [doi:10.1038/onc.2013.214]
123. Tanic, M., Yanowsky, K., Rodriguez-Antona, C., et al., 2012. Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS ONE, 7(6):e38847. [doi:10.1371/journal.pone.0038847]
124. Tanzer, A., Stadler, P.F., 2004. Molecular evolution of a microRNA cluster. J. Mol. Biol., 339(2):327–335. [doi:10.1016/j.jmb.2004.03.065]
125. Tavazoie, S.F., Alarcon, C., Oskarsson, T., et al., 2008. Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451(7175):147–152. [doi:10.1038/nature06487]
126. Taylor, M.A., Sossey-Alaoui, K., Thompson, C.L., et al., 2013. TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J. Clin. Invest., 123(1):150–163. [doi:10.1172/JCI64946]
127. Tsuchiya, Y., Nakajima, M., Takagi, S., et al., 2006. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res., 66(18):9090–9098. [doi:10.1158/0008-5472.CAN-06-1403]
128. Valastyan, S., Chang, A., Benaich, N., et al., 2011. Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes Dev., 25(6):646–659. [doi:10.1101/gad.2004211]
129. Valent, P., Bonnet, D., de Maria, R., et al., 2012. Cancer stem cell definitions and terminology: the devil is in the details. Nat. Rev. Cancer, 12(11):767–775. [doi:10.1038/nrc3368]
130. Wang, B., Zhang, Q.Y., 2012. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J. Cancer Res. Clin. Oncol., 138(10):1659–1666. [doi:10.1007/s00432-012-1244-9]
131. Wang, F.J., Zheng, Z.G., Guo, J.F., et al., 2010. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol. Oncol., 119(3):586–593. [doi:10.1016/j.ygyno.2010.07.021]
132. Wang, S., Huang, J., Lyu, H., et al., 2013. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis., 4(3): e556. [doi:10.1038/cddis.2013.79]
133. Wang, S.H., Bian, C.J., Yang, Z., et al., 2009. miR-145 inhibits breast cancer cell growth through RTKN. Int. J. Oncol., 34(5):1461–1466. [doi:10.3892/Ijo_00000275]
134. Weidhaas, J.B., Babar, L., Nallur, S.M., et al., 2007. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res., 67(23):11111–11116. [doi:10.1158/0008-5472.CAN-07-2858]
135. Wu, H.L., Zhu, S.M., Mo, Y.Y., 2009. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res., 19(4):439–448. [doi:10.1038/cr.2009.18]
136. Xu, Q., Jiang, Y., Yin, Y., et al., 2013. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J. Mol. Cell Biol., 5(1):3–13. [doi:10.1093/Jmcb/Mjs049]
137. Yanaihara, N., Caplen, N., Bowman, E., et al., 2006. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9(3):189–198. [doi:10.1016/j.ccr.2006.01.025]
138. Yang, J., Zhang, Z., Chen, C., et al., 2014. MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through down-regulated expression of Fra-1 proto-oncogene. Oncogene, 33(23): 3014–3023. [doi:10.1038/onc.2013.258]
139. Yu, F., Yao, H., Zhu, P.C., et al., 2007. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 131(6):1109–1123. [doi:10.1016/j.cell.2007.10.054]
140. Yu, F., Deng, H., Yao, H., et al., 2010. miR-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene, 29(29):4194–4204. [doi:10.1038/onc.2010.167]
141. Yu, Z.R., Wang, C.G., Wang, M., et al., 2008. A Cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J. Cell Biol., 182(3): 509–517. [doi:10.1083/jcb.200801079]
142. Zhang, C.M., Zhao, J., Deng, H.Y., 2013. miR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J. Biomed. Sci., 20(1):79. [doi:10.1186/1423-0127-20-79]
143. Zhou, J., Tian, Y., Li, J., et al., 2013. miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem. Biophys. Res. Commun., 433(2):207–212. [doi:10.1016/j.bbrc.2013.02.084]
144. Zhu, S., Sachdeva, M., Wu, F., et al., 2010. Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene, 29(12):1763–1772. [doi:10.1038/onc.2009.459]
145. Zhu, S.M., Si, M.L., Wu, H.L., et al., 2007. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem., 282(19):14328–14336. [doi:10.1074/jbc.M611393200]
146. Zoon, C.K., Starker, E.Q., Wilson, A.M., et al., 2009. Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Rev. Mol. Diagn., 9(5):455–467. [doi:10.1586/erm.09.25]
147. Zou, C., Xu, Q., Mao, F., et al., 2012. miR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle, 11(11):2137–2145. [doi:10.4161/cc.20598]